Chronic Obstructive Pulmonary Disease Clinical Trial
— OCEANOfficial title:
A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-national, Phase III, Efficacy and Safety Study of Inhaled Formoterol 4.5 μg and 9 μg Twice Daily in Japanese and European Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.
Status | Completed |
Enrollment | 613 |
Est. completion date | April 2009 |
Est. primary completion date | April 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Males or females aged above 40 with a clinical diagnosis of COPD and current COPD symptoms - Current or previous smoker with a smoking history of 10 or more pack years - Lung function parameters: FEV1/FVC < 70%, post-bronchodilator and post-bronchodilator FEV1 < 80% of predicted normal value Exclusion Criteria: - History and/or current clinical diagnosis of asthma or atopic diseases such as allergic rhinitis - Use of inhaled glucocorticosteroids within 4 weeks prior to Visit 2 - Any relevant cardiovascular disorder as judged by the investigator or any current respiratory tract disorder other than COPD. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Bulgaria | Research Site | Gabrovo | |
Bulgaria | Research Site | Lovech | |
Bulgaria | Research Site | Pleven | |
Bulgaria | Research Site | Russe | |
Bulgaria | Research Site | Sofia | |
Bulgaria | Research Site | Stara Zagora | |
Bulgaria | Research Site | Troyan | |
Bulgaria | Research Site | Varna | |
Japan | Research Site | Asahikawa | Hokkaido |
Japan | Research Site | Chitose | Hokkaido |
Japan | Research Site | Chiyoda | Tokyo |
Japan | Research Site | Hiroshima | |
Japan | Research Site | Kagoshima | |
Japan | Research Site | Katano | Osaka |
Japan | Research Site | Kawasaki | Kangawa |
Japan | Research Site | Kishiwada | Osaka |
Japan | Research Site | Kochi | |
Japan | Research Site | Kyoto | |
Japan | Research Site | Morioka | Iwate |
Japan | Research Site | Nagoya | Aichi |
Japan | Research Site | Naka-gun | Ibaraki |
Japan | Research Site | Noda | Chiba |
Japan | Research Site | Obihiro | Hokkaido |
Japan | Research Site | ORA | Gunma |
Japan | Research Site | Osaka | |
Japan | Research Site | OTA | Gunma |
Japan | Research Site | Sapporo | Hokkaido |
Japan | Research Site | Sendai | Miyagi |
Japan | Research Site | Seto | Aichi |
Japan | Research Site | Takatsuiki | Osaka |
Japan | Research Site | Tomakomai | Hokkaido |
Japan | Research Site | Touon | Ehime |
Japan | Research Site | UBE | Yamaguchi |
Japan | Research Site | Wakayama | |
Japan | Research Site | Yabu | Hyogo |
Japan | Research Site | Yanagawa | Fukuoka |
Romania | Research Site | Bucharest | |
Romania | Research Site | Bucuresti | |
Romania | Research Site | Constanta | |
Romania | Research Site | Deva | Hunedoara |
Romania | Research Site | Iasi | |
Russian Federation | Research Site | Kazan | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | St. Petersburg | |
Ukraine | Research Site | Dnipropetrovsk | |
Ukraine | Research Site | Donetsk | |
Ukraine | Research Site | Kharkiv | |
Ukraine | Research Site | Kyiv |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Bulgaria, Japan, Romania, Russian Federation, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose | FEV1 (expressed as litres [L]) is a spirometric measure of lung function. FEV1 was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value. | from baseline up to 12 weeks | No |
Secondary | Forced Vital Capacity (FVC) 60 Minutes Post-dose | Forced Vital Capacity (FVC) is a spirometric measure of lung function. FVC was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value | from baseline up to 12 weeks | No |
Secondary | FEV1 Pre-dose | Lung function (FEV1) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value | baseline at week 0 and pre-dose at weeks 4, 8 and 12 | No |
Secondary | FVC Pre-dose | Lung function (FVC) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value | baseline at week 0 and pre-dose at weeks 4, 8 and 12 | No |
Secondary | FEV1 5 Minutes Post-dose | Lung function (FEV1) was measured 5 minutes after the first dose of study drug. The results are expressed as a percentage in relation to the baseline value | baseline and 5 minutes anter first dose | No |
Secondary | FVC 5 Minutes Post-dose | Lung function (FVC) was measured 5 minutes after the first dose of study drug, The results are expressed as a percentage in relation to the baseline value | baseline and 5 minutes anter first dose | No |
Secondary | Change in Peak Expiratory Flow (PEF), Morning | Patients were asked to measure and record lung function (peak expiratory flow [PEF] measured in the morning). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value | run-in period and 12 week | No |
Secondary | Change in Peak Expiratory Flow (PEF), Evening | Patients were asked to measure and record lung function (peak expiratory flow [PEF] measured in the evening). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value | run-in period and 12 week | No |
Secondary | Change in Night-time Awakenings Due to Symptoms | Patients were asked to record the night-time awakenings due to symptoms (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value | run-in period up to 12 weeks | No |
Secondary | Breathlessness | Patients were asked to record breathlessness (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value | run-in period up to 12 weeks | No |
Secondary | Cough | Patients were asked to record cough (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value | run-in period up to 12 weeks | No |
Secondary | Use of Reliever Medication | Patients were asked to record reliever medication use. Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value | 12 weeks (end of run-in to last visit) | No |
Secondary | St George's Respiratory Questionnaire (SGRQ) | Patients were asked to complete the St George's Respiratory Questionnaire (SGRQ). Subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life. A score of 0 indicates the best possible status. Results are expressed as the change from baseline score with a decrease in score indicating improvement. | 12 weeks (end of run-in to last visit) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|